KRAS and pancreatic ductal adenocarcinoma: In pancreatic ductal adenocarcinoma, Hayashi et al. [15] found that cell-in-cell structures predict prognosis, and associate with poorly-differentiated tumors, TP53 mutations, KRAS amplification and MYC amplification.